Trial Profile
Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Melphalan; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CARTHADEX
- Sponsors Erasmus MC; Onyx Pharmaceuticals
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results of 4 dose levels presented at the 58th Annual Meeting and Exposition of the American Society of Hematology